Thus, we selected PKI-587 (PKI, gedatolisib), a highly potent dual panPI3K/mTOR inhibitor [22] which was granted fast FDA track designation [23] and breakthrough therapy designation [24] in 2022 for HR+/HER2− breast cancer that failed to respond to CDK4/6 therapy. This evidence concerns the gene CDK4 and breast carcinoma.